Clinical and pharmacological group: & nbsp

Nootropics

Included in the formulation
  • Anvifen®
    capsules inwards 
    Anvilab, OOO     Russia
  • Noofen®
    capsules inwards 
    Olainfarm, AO     Latvia
  • Fenibut
    pills inwards 
  • Fenibut
    pills inwards 
    ORGANICS, JSC     Russia
  • Fenibut
    pills inwards 
    BELMEDPREPARATY, RUP     Republic of Belarus
  • Fenibut
    pills inwards 
  • Fenibut
    pills inwards 
  • Fenibut
    pills inwards 
    TRIM, LLC     Russia
  • Fenibut-LekT
    pills inwards 
    PATENT-FARM, CJSC     Russia
  • АТХ:

    N.06.B   Psychostimulants and nootropic drugs

    Pharmacodynamics:

    Anxiolytic and nootropic agent, is a gamma-amino-beta-phenylbutyric acid hydrochloride. It facilitates GABA-mediated transmission of nerve impulses to the central nervous system (has a direct effect on GABA receptors), has a tranquilizing, psychostimulating, antiplatelet and antioxidant effect.

    Improves the functional state of the brain due to the normalization of tissue metabolism and effects on cerebral circulation (increases the volume and linear speed of cerebral blood flow, reduces the tone of the vessels of the brain, improves microcirculation, and has antiaggregant effect).Promotes the reduction or disappearance of feelings of anxiety, tension, anxiety and fear, normalizes sleep, has some anticonvulsant effect.

    Does not affect cholino- and adrenergic receptors.

    It prolongs the latent period and shortens the duration and severity of nystagmus.

    Reduces the manifestations of asthenia and vasovegetative symptoms (including headache, a sense of heaviness in the head, sleep disorders, irritability, emotional lability).

    Increases mental performance, improves psychological performance (attention, memory, speed and accuracy of sensory-motor reactions).

    At the course reception increases physical and mental efficiency, improves memory, normalizes sleep; improves the condition of patients with motor and speech disorders. Asthenia patients improve their health from the first days of therapy; increases interest and initiative without sedative action and excitement. When used after severe head injury, it increases the number of mitochondria in the perifocal areas and improves the course of bioenergetic processes in the brain.

    With neurogenic lesions of the heart and stomach normalizes the processes of lipid peroxidation.In elderly people does not cause congestion and excessive lethargy, a relaxing aftereffect is most often absent. Improves microcirculation in the tissues of the eye, reduces the inhibitory effect of ethanol on the central nervous system. Malotoxic.

    Pharmacological effects

    Anxiolytic. Improvement of metabolism in the central nervous system.

    Pharmacokinetics:

    Well penetrates into all tissues of the body and through the BBB (in the brain tissue penetrates about 0.1% of the administered dose of the drug, and in young people and the elderly to a much greater extent). Evenly distributed in the liver and kidneys. Metabolized in the liver - 80-95%, metabolites are pharmacologically inactive. Do not cumulate. After 3 hours begins to excrete kidneys, while the concentration in the brain tissue is not reduced. About 5% is excreted by the kidneys unchanged, in part - with bile.

    Indications:

    Asthenic and anxiety-neurotic states. Anxiety, fear, anxiety, obsessive-compulsive disorder, psychopathy, insomnia. Vestibular disorders, prevention of motion sickness, Meniere's disease.


    V.F10-F19.F10.3   Mental and behavioral disorders caused by alcohol use - withdrawal symptoms

    V.F40-F48.F40.9   Phobic anxiety disorder, unspecified

    V.F40-F48.F41.2   Mixed anxiety and depressive disorder

    V.F40-F48.F41.9   Anxiety disorder, unspecified

    V.F40-F48.F42.0   Predominantly obsessive thoughts or reflections

    V.F40-F48.F48   Other neurotic disorders

    V.F40-F48.F48.9   Neurotic disorder, unspecified

    V.F60-F69.F60.2   Dissocial personality disorder

    V.F90-F98.F95   Tiki

    V.F90-F98.F98.0   Enuresis of inorganic nature

    V.F90-F98.F98.5   Stuttering [stammering]

    VI.G40-G47.G47.0   Disturbances of falling asleep and maintaining sleep [insomnia]

    VIII.H80-H83.H81.0   Ménière's disease

    VIII.H80-H83.H81.9   Violation of vestibular function, unspecified

    VIII.H80-H83.H83.0   Labyrinthite

    XVIII.R40-R46.R42   Dizziness and dizziness

    XVIII.R40-R46.R45.1   Anxiety and Excitement

    XVIII.R50-R69.R53   Malaise and fatigue

    XIX.T66-T78.T75.3   Motion Slicking

    Contraindications:

    Hypersensitivity, breast-feeding. With care - diseases of the digestive tract.

    Carefully:

    Use with caution in pregnancy, during lactation.

    C use with caution in erosive and ulcerative lesions of the digestive tract, liver failure.

    Pregnancy and lactation:

    Pregnancy

    The category of FDA recommendations is not defined. Adequate and well-controlled studies on humans and animals have not been conducted. Do not apply.

    Lactation

    There is no information on the penetration into breast milk.

    Dosing and Administration:

    With dysfunction of the vestibular apparatus - 750 mg 3-4 times a day. The course of treatment is 5-7 days, then - 250 mg / day once for 5 days.

    With mild degree of dysfunction - 250 mg twice a day for 5-7 days, then - 250 mg / day once for 7-10 days.

    When violations of the vestibular function of the vascular or traumatic etiology - 250 mg 3 times a day. The course of treatment is 12 days.

    Prophylaxis of motion sickness. For 250-500 mg once for 1 hour before the proposed journey.

    Alcohol abstinence, psychopathological and somatovegetative disorders. For 250-500 mg 3 times a day and 750 mg at night, gradually lowering the dose.

    Residual effects after head trauma, premedication. The drug is taken orally (before meals). Adults appoint 250-500 mg 3 times a day.

    The average therapeutic daily dose is 750-2500 mg. The course of treatment 4-6 weeks. The maximum single dose for adults is 750 mg, for people over 60 years, 500 mg.

    Use in children

    Stuttering, tics, enuresis. Up to 8 years: 50-100 mg. 8-14 years: 250 mg 3 times a day. The maximum single dose for children under 8 years is 150 mg, 8-14 years - 300 mg.

    Side effects:

    Drowsiness, nausea.

    Overdose:

    Not described. Treatment is symptomatic.

    Interaction:

    Sleeping, narcotic, neuroleptic and anticonvulsant means - strengthening and lengthening their effect.

    Special instructions:

    Monitoring: indicators of peripheral blood and liver function.

    The use of aminophenylbutyric acid in combination with propranolol and its isolated use most effectively increase the temperature stability, provide a normal supply of oxygen to the body and maintain high performance in conditions of body overheating (single intake as a means of individual protection). Not represented in US and UK Pharmacopoeias. During the treatment period it is necessary to refrain from potentially dangerous activities requiring increased attention and high speed of psychomotor reactions

    Instructions
    Up